Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2,000
Single User License Price INR 135
Corporate User License Price USD 6,000
Corporate User License Price INR 405
Site License Price USD 4,000
Site License Price INR 270
Request a Quote

Report Title

Endometrial Cancer - Pipeline Review, H1 2018

Quote Request for License Type
License Type Price  
Single User License USD 2,000
Site License USD 4,000
Enterprise Wide License USD 6,000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Endometrial Cancer - Pipeline Review, H1 2018


Quote Request for License Type
License Type Price  
Single User License USD 2,000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Endometrial Cancer - Pipeline Review, H1 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Endometrial Cancer - Pipeline Review, H1 2018



Executive Summary

Endometrial Cancer - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer - Pipeline Review, H1 2018, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.

Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 44, 49, 1 and 15 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 4 molecules, respectively.

Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

Introduction 7

Endometrial Cancer - Overview 8

Endometrial Cancer - Therapeutics Development 9

Endometrial Cancer - Therapeutics Assesssment 23

Endometrial Cancer - Companies Involved in Therapeutics Development 39

Endometrial Cancer - Drug Profiles 72

Endometrial Cancer - Dormant Projects 768

Endometrial Cancer - Discontinued Products 770

Endometrial Cancer - Product Development Milestones 771

Appendix 784

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Endometrial Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

List of Tables

Number of Products under Development for Endometrial Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Endometrial Cancer - Pipeline by AbbVie Inc, H1 2018

Endometrial Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2018

Endometrial Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018

Endometrial Cancer - Pipeline by Aeterna Zentaris Inc, H1 2018

Endometrial Cancer - Pipeline by AlfaSigma SpA, H1 2018

Endometrial Cancer - Pipeline by Amgen Inc, H1 2018

Endometrial Cancer - Pipeline by ArQule Inc, H1 2018

Endometrial Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2018

Endometrial Cancer - Pipeline by AstraZeneca Plc, H1 2018

Endometrial Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018

Endometrial Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2018

Endometrial Cancer - Pipeline by Bayer AG, H1 2018

Endometrial Cancer - Pipeline by BeiGene Ltd, H1 2018

Endometrial Cancer - Pipeline by BioNTech AG, H1 2018

Endometrial Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H1 2018

Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Endometrial Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2018

Endometrial Cancer - Pipeline by Celsion Corp, H1 2018

Endometrial Cancer - Pipeline by Clovis Oncology Inc, H1 2018

Endometrial Cancer - Pipeline by Corvus Pharmaceuticals Inc, H1 2018

Endometrial Cancer - Pipeline by Cotinga Pharmaceuticals Inc, H1 2018

Endometrial Cancer - Pipeline by CytomX Therapeutics Inc, H1 2018

Endometrial Cancer - Pipeline by Eisai Co Ltd, H1 2018

Endometrial Cancer - Pipeline by Eli Lilly and Co, H1 2018

Endometrial Cancer - Pipeline by Epizyme Inc, H1 2018

Endometrial Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2018

Endometrial Cancer - Pipeline by Exelixis Inc, H1 2018

Endometrial Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Endometrial Cancer - Pipeline by Five Prime Therapeutics Inc, H1 2018

Endometrial Cancer - Pipeline by Fujifilm Holdings Corporation, H1 2018

Endometrial Cancer - Pipeline by GamaMabs Pharma SA, H1 2018

Endometrial Cancer - Pipeline by Genmab A/S, H1 2018

Endometrial Cancer - Pipeline by GlaxoSmithKline Plc, H1 2018

Endometrial Cancer - Pipeline by Glycotope GmbH, H1 2018

Endometrial Cancer - Pipeline by Gradalis Inc, H1 2018

Endometrial Cancer - Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, H1 2018

Endometrial Cancer - Pipeline by Horizon Pharma Plc, H1 2018

Endometrial Cancer - Pipeline by Immunocore Ltd, H1 2018

Endometrial Cancer - Pipeline by ImmunoGen Inc, H1 2018

Endometrial Cancer - Pipeline by Immunomedics Inc, H1 2018

Endometrial Cancer - Pipeline by Incyte Corp, H1 2018

Endometrial Cancer - Pipeline by Innate Pharma SA, H1 2018

Endometrial Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2018

Endometrial Cancer - Pipeline by Leap Therapeutics Inc, H1 2018

Endometrial Cancer - Pipeline by MedImmune LLC, H1 2018

Endometrial Cancer - Pipeline by Merck & Co Inc, H1 2018

Endometrial Cancer - Pipeline by Merck KGaA, H1 2018

Endometrial Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2018

Endometrial Cancer - Pipeline by Mersana Therapeutics Inc, H1 2018

Endometrial Cancer - Pipeline by Merus NV, H1 2018

Endometrial Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2018

Endometrial Cancer - Pipeline by Moderna Therapeutics Inc, H1 2018

Endometrial Cancer - Pipeline by Morphotek Inc, H1 2018

Endometrial Cancer - Pipeline by Novartis AG, H1 2018

Endometrial Cancer - Pipeline by NovaTarg Therapeutics Inc, H1 2018

Endometrial Cancer - Pipeline by OncoResponse Inc, H1 2018

Endometrial Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Endometrial Cancer - Pipeline by Pfizer Inc, H1 2018

Endometrial Cancer - Pipeline by Pharma Mar SA, H1 2018

Endometrial Cancer - Pipeline by Pivot Pharmaceuticals Inc, H1 2018

Endometrial Cancer - Pipeline by PTC Therapeutics Inc, H1 2018

Endometrial Cancer - Pipeline by Puma Biotechnology Inc, H1 2018

Endometrial Cancer - Pipeline by Sanofi, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

AbbVie Inc

Ability Pharmaceuticals SL

Advenchen Laboratories LLC

Aeterna Zentaris Inc

AlfaSigma SpA

Amgen Inc

ArQule Inc

Arrien Pharmaceuticals LLC

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

AVEO Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

BioNTech AG

Biscayne Pharmaceuticals Inc

Boehringer Ingelheim GmbH

CBT Pharmaceuticals Inc

Celsion Corp

Clovis Oncology Inc

Corvus Pharmaceuticals Inc

Cotinga Pharmaceuticals Inc

CytomX Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

Epizyme Inc

Esperance Pharmaceuticals Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Five Prime Therapeutics Inc

Fujifilm Holdings Corporation

GamaMabs Pharma SA

Genmab A/S

GlaxoSmithKline Plc

Glycotope GmbH

Gradalis Inc

Harbin Gloria Pharmaceuticals Co Ltd

Horizon Pharma Plc

Immunocore Ltd

ImmunoGen Inc

Immunomedics Inc

Incyte Corp

Innate Pharma SA

Karyopharm Therapeutics Inc

Leap Therapeutics Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Mersana Therapeutics Inc

Merus NV

Millennium Pharmaceuticals Inc

Moderna Therapeutics Inc

Morphotek Inc

Novartis AG

NovaTarg Therapeutics Inc

OncoResponse Inc

Ono Pharmaceutical Co Ltd

Pfizer Inc

Pharma Mar SA

Pivot Pharmaceuticals Inc

PTC Therapeutics Inc

Puma Biotechnology Inc

Sanofi

SELLAS Life Sciences Group Inc

Shenogen PharmaGroup Ltd

Sutro Biopharma Inc

Syndax Pharmaceuticals Inc

Synthon Holdings BV

Taiho Pharmaceutical Co Ltd

Tesaro Inc

Vyriad Inc

Xencor Inc

Endometrial Cancer Therapeutic Products under Development, Key Players in Endometrial Cancer Therapeutics, Endometrial Cancer Pipeline Overview, Endometrial Cancer Pipeline, Endometrial Cancer Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand